Janssen's Niraparib Receives the US FDA's Breakthrough Therapy Designation for Metastatic Castration-Resistant Prostate Cancer
Shots:
- The breakthrough designation is based on P-II GALAHAD study assessing Niraparib in adult patients with BRCA1/2 gene-mCRPC and DNA-repair gene defects (DRD) prior treated with androgen-receptor targeting therapies and docetaxel
- The FDA's BT designation is granted to expedite the development and regulatory review of an investigational medicine that is intended to treat a serious or life-threatening condition
- Niraparib (PO) is a selective PARP inhibitor- currently being evaluated in P-III MAGNITUDE study assessing niraparib + Zytiga (abiraterone acetate) and prednisone in patients with mPC. Additionally- it is being evaluated in P-Ib/II study of niraparib combination therapies for the treatment of mCRPC
Click here to read full press release/ article
Ref: Janssen | Image: Janssen
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com